• 1201 Citations
  • 18 h-Index
1987 …2018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where David Rotella is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Pharmaceutical Chemistry Medicine & Life Sciences
Enzyme Inhibitors Medicine & Life Sciences
Drug Design Medicine & Life Sciences
Structure-Activity Relationship Medicine & Life Sciences
Drug Discovery Medicine & Life Sciences
Organic Chemistry Medicine & Life Sciences
Phosphodiesterase 5 Inhibitors Medicine & Life Sciences
Preclinical Drug Evaluations Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1987 2018

1 Citation (Scopus)

Discovery of a Stress-Activated Protein Kinase Inhibitor for Lymphatic Filariasis

Tummalapalli, S. R., Bhat, R., Chojnowski, A., Prorok, M., Kreiss, T., Goldberg, R., Canan, S., Hawryluk, N., Mortensen, D., Khetani, V., Zeldis, J., Siekierka, J. & Rotella, D., 8 Mar 2018, In : ACS Medicinal Chemistry Letters. 9, 3, p. 210-214 5 p.

Research output: Contribution to journalArticle

Filarial Elephantiasis
Structure-Activity Relationship
Protein Kinase Inhibitors
Heat-Shock Proteins
Protein Kinases
1 Citation (Scopus)

Expression, purification, and inhibition profile of dihydrofolate reductase from the filarial nematode Wuchereria bancrofti

Tobias, A. M., Toska, D., Lange, K., Eck, T., Bhat, R., Janson, C. A., Rotella, D. P., Gubler, U. & Goodey, N. M., May 2018, In : PLoS ONE. 13, 5, e0197173.

Research output: Contribution to journalArticle

Wuchereria bancrofti
Aminopterin
dihydrofolate reductase
Folic Acid Antagonists
Tetrahydrofolate Dehydrogenase

Comprehensive Medicinal Chemistry III

Chackalamannil, S., Rotella, D. & Ward, S. E., 3 Jun 2017, The Future of Drug Discovery: Drug Discovery Technologies: In Silico Drug Discovery Tools: Experimental Adme and Toxicology: Cancer, Immunology and Inflammation, and Infectious Disease: Biologics Medicine: Cns, Pain, Metabolic Syndrome, Cardiovascular, Tissue Fibrosis and Urinary Incontinence: Case Histories in Recent Drug Discovery. Elsevier Inc., Vol. 1-8. p. 1-4369 4369 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

Biological Products
Medicine
Bispecific Antibodies
Peptide Nucleic Acids
Molecules
4 Citations (Scopus)

Mechanism of inhibition of botulinum neurotoxin type A light chain by two quinolinol compounds

Minnow, Y. V. T., Goldberg, R., Tummalapalli, S. R., Rotella, D. & Goodey, N., 15 Mar 2017, In : Archives of Biochemistry and Biophysics. 618, p. 15-22 8 p.

Research output: Contribution to journalArticle

Hydroxyquinolines
Type A Botulinum Toxins
Light
Tetanus Toxin
Structure-Activity Relationship

Preface

Chackalamannil, S., Rotella, D. & Ward, S. E., 3 Jun 2017, The Future of Drug Discovery: Drug Discovery Technologies: In Silico Drug Discovery Tools: Experimental Adme and Toxicology: Cancer, Immunology and Inflammation, and Infectious Disease: Biologics Medicine: Cns, Pain, Metabolic Syndrome, Cardiovascular, Tissue Fibrosis and Urinary Incontinence: Case Histories in Recent Drug Discovery. Elsevier Inc., Vol. 1-8. p. v-vi

Research output: Chapter in Book/Report/Conference proceedingForeword/postscript